Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
How we grade evidence
Its initiation criteria include age 18 or older, qualifying BMI and comorbidity criteria, inadequate response or intolerance to two oral weight-management medicines, participation in a comprehensive weight-management program, no dual GLP-1 therapy, and use of preferred products unless a medical exception applies
Eloralintide Novos delays and the strategy behind them Lillys surprising phase 2 results (up to 20% weight loss) Combination therapies with tirzepatide or retatrutide 22:30 FDA Pipeline Acceleration Potential removal of traditional phase 3 trials How this speeds up the arrival of next-generation therapies 24:15 Oral GLP-1 Small Molecules (Structure Therapeutics) Alaniglipron data and the stock surge Comparisons to orforglipron and past failures like denuglipron Why Dave remains skeptical 28:40 Sponsor Break: Shed & Shapa Access, coaching, and patient support Using a numberless scale to build a healthier relationship with weight tracking 31:10 Counterfeit Ozempic Warning New fake lot discovered in U.S
Skin changes accompanied by fever (potential allergic reaction or infection)
HSA or FSA reimbursement may be available depending on your individual plan
Similarly, the estimated monthly prices for GLP-1 agonists were calculated to be between US$ 0.75 and US$ 72.49, whereas the actual monthly price in the U.S
US$ 26.59
US$ 28.43
US$ 29.14
US$ 24.39
